Sildenafil for treatment of erectile dysfunction in men with diabetes - A randomized controlled trial

被引:448
作者
Rendell, MS
Rajfer, J
Wicker, PA
Smith, MD
机构
[1] Creighton Diabet Ctr, Omaha, NE 68131 USA
[2] Univ Calif Los Angeles, Los Angeles Cty Harbor Med Ctr, Torrance, CA USA
[3] Pfizer Inc, Pfizer Cent Res, Groton, CT 06340 USA
[4] Pfizer Cent Res, Sandwich, Kent, England
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 1999年 / 281卷 / 05期
关键词
D O I
10.1001/jama.281.5.421
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Erectile dysfunction is common in men with diabetes. Objective To assess the efficacy and safety of oral sildenafil citrate in the treatment of erectile dysfunction in men with diabetes. Design A multicenter, randomized, double-blind, placebo-controlled, flexible dose-escalation study conducted May through November 1996. Setting Patients' homes and 19 clinical practice centers in the United States. Patients A total of 268 men (mean age, 57 years) with erectile dysfunction (mean duration, 5.6 years) and diabetes (mean duration, 12 years). Interventions Patients were randomized to receive sildenafil (n = 136) or placebo (n = 132) as needed, but not more than once daily, for 12 weeks. Patients took the study drug or placebo 1 hour before anticipated sexual activity. The starting dose of sildenafil citrate was 50 mg; with the option to adjust the dose to 100 mg or 25 mg based on efficacy and tolerability, to be taken as needed. Main Outcome Measures Self-reported ability to achieve and maintain an erection for sexual intercourse according to the International Index of Erectile Function and adverse events. Results Two hundred fifty-two patients (94%) completed the study(131/136 in the sildenafil group, 121/132 in the placebo group). By intention-to-treat analysis, at 12 weeks, 74 (56%) of 131 patients in the sildenafil group reported improved erections compared with 13 (10%) of 127 patients in the placebo group (P < .001). The proportion of men with at least 1 successful attempt at sexual intercourse was 61% (71/117) for the sildenafil group vs 22% (25/114) for the placebo group (P < .001). Adverse events related to treatment were reported for 22 (16%) of 136 patients taking sildenafil and 1 (1%) of 132 patients receiving placebo. The most common adverse events were headache (11% sildenafil, 2% placebo), dyspepsia (9% sildenafil, 0% placebo), and respiratory tract disorder (6% sildenafil, 2% placebo), predominantly sinus congestion or drainage. The incidence of cardiovascular adverse events was comparable for both groups (3% sildenafil, 5% placebo). Conclusion Oral sildenafil is an effective and well-tolerated treatment for erectile dysfunction in men with diabetes.
引用
收藏
页码:421 / 426
页数:6
相关论文
共 25 条
  • [1] PHYSIOLOGY OF PENILE ERECTION
    ANDERSSON, KE
    WAGNER, G
    [J]. PHYSIOLOGICAL REVIEWS, 1995, 75 (01) : 191 - 236
  • [2] FACTORS PREDICTING EFFICACY OF PHENTOLAMINE-PAPAVERINE INTRACORPOREAL INJECTION FOR TREATMENT OF ERECTILE DYSFUNCTION IN DIABETIC MALE
    BELL, DSH
    CUTTER, GR
    HAYNE, VB
    LLOYD, LK
    [J]. UROLOGY, 1992, 40 (01) : 36 - 40
  • [3] Boolell M, 1996, Int J Impot Res, V8, P47
  • [4] BRAUNSTEIN GD, 1987, MT SINAI J MED, V54, P236
  • [5] ROLE OF NITRIC BRIDE IN THE PHYSIOLOGY OF ERECTION
    BURNETT, AL
    [J]. BIOLOGY OF REPRODUCTION, 1995, 52 (03) : 485 - 489
  • [6] Nitric oxide in the penis: Physiology and pathology
    Burnett, AL
    [J]. JOURNAL OF UROLOGY, 1997, 157 (01) : 320 - 324
  • [7] *CDCP, 1997, NAT DIAB FACT SHEET
  • [8] DETEJADA IS, 1988, UROL CLIN N AM, V15, P17
  • [9] DROLLER MJ, 1993, JAMA-J AM MED ASSOC, V270, P83
  • [10] IMPOTENCE AND ITS MEDICAL AND PSYCHOSOCIAL CORRELATES - RESULTS OF THE MASSACHUSETTS MALE AGING STUDY
    FELDMAN, HA
    GOLDSTEIN, I
    HATZICHRISTOU, DG
    KRANE, RJ
    MCKINLAY, JB
    [J]. JOURNAL OF UROLOGY, 1994, 151 (01) : 54 - 61